Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease.
The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018.
The company was incorporated in 2017 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 125 |
| CEO | Jason Coloma |
Contact Details
Address: 171 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 850 5070 |
| Website | mazetx.com |
Stock Details
| Ticker Symbol | MAZE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001842295 |
| ISIN Number | US5787841007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | Chief Executive Officer and Director |
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Courtney J. Phillips J.D. | General Counsel and Corporate Secretary |
| Amy Bachrodt | Senior Vice President of Finance and Chief Financial Officer |
| Vipin Vijayakumar | Vice President of Research & Development Infrastructure and Operations |
| Matt Krause | Senior Vice President of Human Resources |
| Atul Dandekar | Chief Strategy and Business Officer |
| Nazila Habibizad | Senior Vice President of Technical Operations and Supply Chain |
| Maarten Hoek | Senior Vice President of Research |
| Winston Tse | Senior Vice President of Drug Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 9, 2025 | SCHEDULE 13G | Filing |
| May 9, 2025 | SCHEDULE 13G | Filing |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Mar 31, 2025 | 10-K | Annual Report |